| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Imsidolimab (ANB019) - (GEMINI-1) | Generalized pustular psoriasis | BLA Filing | Data Released | Intravenous | Immunology |
| Vanda Pharmaceuticals Inc. | Tradipitant - (EPIONE 1) | Atopic dermatitis | Phase 3 | Trial Discontinued | Oral | Immunology |
| Vanda Pharmaceuticals Inc. | HETLIOZ (tasimelteon) | Delayed sleep phase disorder (DSPD) | Phase 3 | Ongoing | oral | Neurology |
| Vanda Pharmaceuticals Inc. | Tradipitant - (EPIONE 2) | Atopic dermatitis | Phase 3 | Trial Discontinued | Oral | Immunology |
| Vanda Pharmaceuticals Inc. | Tradipitant - (ODYSSEY VLY-686-3501) | Pneumonia associated with COVID-19 | Phase 3 | Trial Discontinued | Oral | COVID-19 |
| Vanda Pharmaceuticals Inc. | VQW-765 - (Study 2201) | Social and Performance Anxiety | Phase 2 | Data Released | Oral | Psychiatric |
| Vanda Pharmaceuticals Inc. | VSJ-110 | Allergic Conjunctivitis | Phase 2 | Trial Planned | Oral | Opthalmic |
| Vaxart Inc. | VXA-CoV2-1 - (XBB) | COVID-19 Vaccine (oral) | Phase 2b | Enrollment Initiation | oral | COVID-19 |